The Role of Pre-Clinical Bleomycin Models in IPF Drug Development
In this article, TherapeutAix has come together with one of our partners, OracleBio, a provider of Quantitative Digital Pathology services supporting pharma and biotech R&D, to provide our collective thoughts on the use and value of the pre-clinical bleomycin model in drug development for Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive lung disease with […]
Christmas 2020 roundup from the TherapeutAix team
As 2020 draws to a close, the team at TheraeutAix has been looking back and reflecting on the last 12 months. Here’s a recap. A pandemic that changed a lot Let’s start with the obvious. The coronavirus pandemic challenged how we engaged with colleagues, conferences and in networking. We enjoyed our only in person meeting […]
Challenges in inhaled drug therapy
In the first blog of this series1, we highlighted that, despite the potential advantages, there appear to be only a few opportunities pursuing the inhaled route of delivery in IPF. Our perception is that there is a “double whammy” here – a general nervousness in the Pharma and Investor community regarding inhalation per se and […]
Drug Development in IPF
Drug development in Idiopathic Pulmonary Fibrosis (IPF) remains challenging. The pharmacological properties of the two approved drugs, pirfenidone and nintedanib, need to be considered when selecting and developing new drug candidates. We discuss the challenges and opportunities in our new review in Drug Discovery Today. We probably don’t need to highlight the fact that despite […]
Targeted Delivery in IPF: Inhalation Therapy
As part of a four-part series, we are looking at targeted delivery in idiopathic pulmonary fibrosis (IPF). This week, we focus on inhalation therapy after following with interest the progress of the inhaled formulation of pirfenidone (AP01, Avalyn Pharma). This approach delivers high concentrations of a drug already established as an effective oral therapy in […]
Alderley Analytical and Peak Proteins join the TherapeutAix Network
Following a recent collaboration, TherapeutAix is delighted to announce the addition of Alderley Analytical and Peak Proteins as network partners. TherapeutAix has joined with Alderley Analytical, which provides specialist bioanalytical services to support drug development programmes, and Peak Proteins, which offers protein expression and purification, protein crystallography, and protein mass spectrometry. The bespoke and dedicated […]
TherapeutAix turns two!
This September, TherapeutAix is two years old. Here, we look back on the past 12 months, and take a sneak peek into the future. Our Customers Our core mission is to help bring molecules with promise to life – and we are helping more customers in planning and navigating their drug discovery and development projects. […]
Common denominators in fibrotic lung disease
With fibrotic disease being one of our areas of interest, it has been highly interesting to follow the news in the past six months or so around nintedanib. It is one of only two approved drugs for idiopathic pulmonary fibrosis, IPF. IPF continues to be a focus area for drug development. Even though its root […]
2019 Round Up – A Full Year!
With 2019 coming to a close, we’re reflecting on a year filled with activities including: advising clients on their projects, expanding our network, participating in and presenting at international conferences, and establishing a workshop format for project review and strategy conception. Here’s a look at some of our highlights: Initial review Initial review is our […]
TherapeutAix to present at the Anti-Fibrotic Drug Development Summit in Boston
We are proud partners for the 3rd Annual Anti-Fibrotic Drug Development Summit (AFDD) which will take place on November 18-20th in Boston. Keynote speakers for the event include Glenn Rosen from Coherus Biosciences, Lisa Hazelwood from Abbvie, Matthew Breyer from Janssen, Rozsa Schlenker-Herceg from Boehringer-Ingelheim, Tim Johnson from UCB and Zoe Johnson from iOnctura. The […]